Sanai Health Industry Group Company Limited provided group earnings guidance for the year ended December 31, 2023. For the period, the company expected that the Group will record a significant decrease in revenue and gross profit margin, which resulted in the substantial decrease in net profit attributable to the owner of the Company of not more than 40% as compared with that for the corresponding period of 2022. The significant decrease in revenue and gross profit margin was mainly attributable to the decrease in sales volume of self-manufactured pharmaceutical products and substantial increase in the general costs of traditional Chinese herb materials in the PRC during the Reporting Period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.028 HKD | 0.00% | +3.70% | -56.25% |
1st Jan change | Capi. | |
---|---|---|
-56.25% | 13.69M | |
+31.52% | 690B | |
+24.84% | 546B | |
-5.21% | 358B | |
+17.02% | 323B | |
+5.01% | 287B | |
+14.00% | 235B | |
+5.48% | 199B | |
-9.94% | 195B | |
+3.98% | 161B |
- Stock Market
- Equities
- 1889 Stock
- News Sanai Health Industry Group Company Limited
- Sanai Health Industry Group Company Limited Provides Group Earnings Guidance for the Year Ended December 31, 2023